Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers
Precigen reported a strong Q2 commercial performance with PAPZIMEOS generating $53.1 million in net product revenue, more than doubling the prior quarter and driving quarterly profitability. The company advanced its oncology pipeline, reporting that PRGN-2009 showed a 20-30% objective response rate and 24.6-month median overall survival in a Phase 1 combination study for HPV-driven cancers.
Key figures
- Revenue
- 53100000
- Orr
- 20-30%
- Median os
- 24.6 months
- Annual hpv cases
- 690000
- Exclusivity years
- 7
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.